Antimetastatic activity of a preventive cancer vaccine

Cancer Research

Volumn 67, Issue 22, 2007, Pages 11037-11044

  Nanni, Patrizia ^a   Nicoletti, Giordano ^b   Palladini, Arianna ^a   Croci, Stefania ^a   Murgo, Annalisa ^a   Antognoli, Agnese ^a   Landuzzi, Lorena ^b   Fabbi, Marina ^c   Ferrini, Silvano ^c   Musiani, Piero ^d   Iezzi, Manuela ^d   De Giovanni, Carla ^a   Lollini, Pier Luigi ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Aging Research Center   (Italy)

^e Sezione Cancerologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CANCER VACCINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; INTERLEUKIN 4; PROTEIN ANTIBODY; PROTEIN INHIBITOR;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER PREVENTION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LUNG METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; DISEASE PROGRESSION; IMMUNE SYSTEM; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 36348966738     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2499     Document Type: Article

References (30)

1. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6:204-16.
2. Spisek R, Dhodapkar MV. Immunoprevention of cancer. Hematol Oncol Clin North Am 2006;20:735-50.
3. Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol 2007;142:179-89.
4. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
5. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neutransgenic mice is IFN-g and B cell dependent. J Immunol 2004;173:2288-96.
6. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neucarcinomas . J Clin Invest 2003;111:1161-70.
7. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. Future Oncol 2005;1:57-66.
8. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neutransgenic mice. J Exp Med 2001;194:1195-205.
9. De Giovanni C, Nicoletti G, Landuzzi L, et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004;64:4001-9.
10. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neutransgenic mice. J Exp Med 1998;188:589-96.
11. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/Neup185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
12. Nanni P, Pupa SM, Nicoletti G, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94.
13. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006;176:1750-8.
14. Ferrini S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985;36:337-43.
15. Ambrosino E, Spadaro M, Iezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006;66:7734-40.
16. De Giovanni C, Landuzzi L, Nicoletti G, et al. Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. Int J Cancer 2004;109:200-6.
17. Di Carlo E, Diodoro MG, Boggio K, et al. Analysis of mammary carcinoma onset and progression in HER-2/neuoncog ene transgenic mice reveals a lobular origin. Lab Invest 1999;79:1261-9.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
19. Reilly RT, Gottlieb MB, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
20. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006;212:149-62.
21. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
22. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006;16:115-23.
23. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15.
24. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53:73-8.
25. Rolla S, Nicolo C, Malinarich S, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-33.
26. Singh R, Paterson Y. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 2007;56:927-38.
27. + T cell repertoire against Her-2/neua ntigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 2004;34:752-61.
28. Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 2007;67:1887-92.
29. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-45.
30. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.